“I’m taking charge.”

Ask your health care provider about ZYKADIA® (ceritinib) tablets when you are diagnosed with ALK-positive metastatic NSCLC.

Important Safety Information:

What is the most important information I should know about ZYKADIA?

ZYKADIA may cause serious side effects, such as:

  • Stomach and intestinal (gastrointestinal) problems ZYKADIA may cause stomach and inte...

See More
Approved Use:

What is ZYKADIA?

ZYKADIA is a prescription medicine that is used to treat people with non-small cell lung cancer (NSCLC) that:

    • Is caused by a defect in a gene called anaplastic lymphoma kinase (ALK) and has spread to other parts of the body

It is not known if ZYKADIA is safe and effective in children.



ZYKADIA was studied in ALK+ metastatic NSCLC in 2 clinical trials. One trial looked at patients who were taking it as their first treatment. The other trial looked at patients who were switching to ZYKADIA after receiving a different targeted treatment. 



If you or someone you love is starting ZYKADIA, there are resources available to help you. Find out about financial support, the co-pay card, and other useful programs here.

Learn More